Severe Leukocyte Adhesion Deficiency-I (LAD-I) Lentiviral-Mediated Ex-Vivo Gene Therapy: Ongoing Phase 1/2 Study Results

MLA

Claire Booth, et al. “Severe Leukocyte Adhesion Deficiency-I (LAD-I) Lentiviral-Mediated Ex-Vivo Gene Therapy: Ongoing Phase 1/2 Study Results.” Clinical Immunology, vol. 250, May 2023, p. 109354. EBSCOhost, https://doi.org/10.1016/j.clim.2023.109354.

APA

Claire Booth, Julian Sevilla, Maria Chitty Lopez, Elena Almarza, Josune Zubicaray, Kritika Chetty, Theodore Moore, Juan Bueren, Jonathan Schwartz, & Donald Kohn. (2023). Severe Leukocyte Adhesion Deficiency-I (LAD-I) Lentiviral-Mediated Ex-Vivo Gene Therapy: Ongoing Phase 1/2 Study Results. Clinical Immunology, 250, 109354. https://doi.org/10.1016/j.clim.2023.109354

Chicago

Claire Booth, Julian Sevilla, Maria Chitty Lopez, Elena Almarza, Josune Zubicaray, Kritika Chetty, Theodore Moore, Juan Bueren, Jonathan Schwartz, and Donald Kohn. 2023. “Severe Leukocyte Adhesion Deficiency-I (LAD-I) Lentiviral-Mediated Ex-Vivo Gene Therapy: Ongoing Phase 1/2 Study Results.” Clinical Immunology 250 (May): 109354. doi:10.1016/j.clim.2023.109354.